Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda

NEW YORK, November 4, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Clovis Oncology, Inc. (NASDAQ: CLVS), Theravance Inc. (NASDAQ: THRX), Charles River Laboratories International, Inc. (NYSE: CRL), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On October 29, 2013, Gilead Sciences Inc. (Gilead Sciences) announced its Q3 2013 results. Gilead Sciences registered total revenues of $2.8 billion in Q3 2013, up 14.7% YoY. Net income attributable to the Company came in at $788.6 million in Q3 2013, up 16.7% YoY. Gilead reported diluted EPS of $0.47 in Q3 2013, up 9.3% YoY. The Company also raised its full-year 2013 guidance for net product sales to be in the range of $10.3 billion to $10.4 billion. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9898_GILD]

--

Clovis Oncology, Inc. Research Report

On October 27, 2013, Clovis Oncology, Inc. (Clovis) announced updated findings from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686. According to Clovis, CO-1686 is its novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. Patrick J. Mahaffy, President and CEO of Clovis, stated, "CO-1686 continues to demonstrate impressive activity and is very well tolerated in these heavily pre-treated patients." Mahaffy continued, "Additionally, the initial pharmacokinetic and safety data from patients in the ongoing Phase I dose-finding study with the hydrobromide formulation are very promising. We are very optimistic about this new formulation since we are already seeing such encouraging results with an inferior formulation at a suboptimal dose. We look forward to identifying the recommended Phase II dose for CO-1686 and quickly proceeding into our first registration study." The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS]

--

Theravance Inc. Research Report

On October 24, 2013, Theravance Inc. (Theravance) released its Q3 2013 results. Theravance registered revenue from collaborative arrangements of $0.4 million in Q3 2013, compared to revenue from collaborative arrangements of $1.4 million in Q3 2012. The Company posted net loss of $47.0 million in Q3 2013, compared to net loss of $34.7 million in Q3 2012. Theravance reported diluted loss per share of $0.44 in Q3 2013, compared to diluted loss per share of $0.37 in Q3 2012. Rick E. Winningham, CEO of Theravance, commented, "We are very pleased to announce that GSK recently began shipping BREO ELLIPTA into the US market." Winningham added, "Theravance is in a strong position as we look forward to other significant events prior to year-end: a potential decision on RELVAR ELLIPTA in the EU, a PDUFA goal date in December 2013 for ANORO ELLIPTA and results from a Phase 2 study of TD-9855 in ADHD. We are also very excited and working towards the successful completion of the separation of Theravance, Inc. into two companies, Theravance, Inc., A Royalty Management Company and Theravance Biopharma." The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fa70_THRX]

--

Charles River Laboratories International, Inc. Research Report

On October 29, 2013, Charles River Laboratories International, Inc. (Charles River) released its Q3 2013 results (period ended September 28, 2013) from continuing operations. Charles River registered total net sales of $292.1 million, up 4.8% YoY in Q3 2013. The Company posted net income attributable to common shareholders of $30.9 million, up 40.5% YoY and diluted EPS of $0.64, up 39.1% YoY in Q3 2013. Commenting on the results, James C. Foster, Chairman, President, and CEO, Charles River, said, "The efforts we have made to improve our operating efficiency, to maintain and enhance scientific expertise, to effectively deploy sales resources and to broaden the portfolio through targeted acquisitions have successfully positioned Charles River as the partner of choice for early-stage drug development. Demand trends are more favorable: global pharmaceutical clients are outsourcing more as they reduce infrastructure and the funding environment appears to have improved for biotechnology companies. We are leveraging all of these factors to win market share and drive sales and earnings growth. This is evident in our third-quarter results, which were highlighted by mid-single-digit sales growth for both segments, as well as meaningful margin expansion in our Preclinical Services segment."

The Full Research Report on Charles River Laboratories International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/a37e_CRL]

--

Acorda Therapeutics, Inc. Research Report

On October 29, 2013, Acorda Therapeutics, Inc. (Acorda) announced that it will host a Research and Development (R&D) Day for the investment community on Tuesday, November 5, 2013 from 9:00 a.m. to 12:00 p.m. Acorda reported that the event will be held in New York City (450 East 29th Street at First Avenue). The Company also informed that a live webcast and replay will be available to interested parties through its website. The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d67c_ACOR]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner